Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03655002
Title IRX-2, Cyclophosphamide, and Nivolumab in Treating Participants With Recurrent or Metastatic and Refractory Liver Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

hepatocellular carcinoma


Cyclophosphamide + IRX-2 + Nivolumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.